La filière rassemblée lors du WORKSHOP O&OoC à Paris
Retrouvez-nous au prochain événement phare des organoïdes et organes sur puce (O&OoC) le 3 avril à l'Institut Curie de Paris organisé par F3OCI ! 📍Nous serons présents en tant que CRO préclinique, fournisseur de services in vitro et in vivo et utilisant des organes-sur-puces dans le cadre du programme BIO-DIAMOND. Nous sommes fiers de sponsoriser ce rendez-vous des chercheurs académiques, biotechnologies et groupes pharmaceutiques de la filière ! Dr Valentin Tallandier, in vitro preclinical Project leader, présentera un pitch à 16:45 – 17:00
See you at the AAN 2025 Annual Meeting in San Diego
📌 Let's meet in San Diego (USA) - April 5-9, 2025 - booth #2043 Our team will be delighted to welcome you at the AAN 2025 Annual Meeting, "The best and largest gathering for neurologists and neuroscience professionals"! This year, we'll be exhibiting at booth #2043 where you'll discover our relevant & translatable in vitro and in vivo solutions for neurology & neurovascular disorders. 🧠 You'll learn more about Brain-on-Chip for PoC on your targets, models of proteinopathies & other neuronal injuries, our
Visit our booth & poster at AD/PD 2025 conference in April
📌 See you in Vienna (Austria) - from 1st to 5th April 2025! We are participating in the 40th AD/PD 2025 as a preclinical CRO expert in AD's and PD's disease research . 📅 Stop by our booth #25 Alzheimer’s & Parkinson’s Diseases Conference is a leading event in the field of neurodegenerative diseases and this year we are exhibiting on booth #25 to present our in vitro & in vivo services dedicated to AD's & PD's translational neuroscience, especially focused on proteinopathies
Technical Note: High-content imaging of brain-on-chip microfluidic devices using PreciScan intelligent acquisition.
Brain-on-chips (BoC) are innovative tools that simulate complex brain environments, enhancing our understanding of neurodegenerative diseases (NDDs). While a range of BoC platforms have been developed to model diverse NDD pathophysiologies, the various channel architectures of these microfluidic devices present challenges in image acquisition and analysis. High-content imaging protocols must be adaptable to these differing designs. This Technical Note, developed by Revvity in collaboration with ETAP-Lab, demonstrates an automated image acquisition protocol for BoC microfluidic devices. The protocol utilizes the Operetta
Exciting research publication from our cardiology lab SYNCROSOME as co-author
Cardiovascular diseases (CVDs) are the leading cause of global mortality. That's why we are proud to share a groundbreaking study titled "Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers". Liu, Sophia et al. iScience, Volume 28, Issue 2, 111814 This study highlights the potential of Urolithin A (UA), a post-biotic and mitophagy activator, to improve heart health by addressing mitochondrial dysfunctions. Preclinical model results show reduced cardiac dysfunction, while human trials indicate significant reductions
Let’s meet at AD’s & PD’s Drug Development Summit in Boston!
We are thrilled to announce our participation in the 13th Alzheimer’s & Parkinson’s Drug Development Summit as a solution provider and preclinical CRO expert in AD's and PD's disease studies. This summit is a unique opportunity to unite new faces across biotech and pharma, capitalize on groundbreaking progress, and accelerate the development of transformative neurodegenerative therapies. 📅 If you're attending the conference, book a meeting with Jérome BERNARD who will be in Boston all the week by clicking here. Let'discover ETAP-Lab's dedicated